P2Y12 shRNA normalizes inflammatory dysfunctional hepatic glucokinase activity in type 2 diabetic rats.

Lin Li, Jingjian Yang, Baoe Liu, Yuting Zou, Minghao Sun, Zijing Li, Runan Yang, Xiumei Xu, Lifang Zou, Guilin Li, Shuangmei Liu, Guodong Li, Shangdong Liang

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020 Dec

filter terms:

The celiac ganglion projects its postganglionic (including purinergic) fibers to the liver. P2Y12 receptor is one of the P2Y family members. We found that the expression levels of P2Y12 receptor in both celiac ganglia and liver were increased in type 2 diabetes mellitus (T2DM) rats which also displayed an enhanced activity of celiac sympathetic nerve discharge (SND). In addition, a marked decrease of hepatic glucokinase (GK) expression was accompanied by reduced hepatic glycogen synthesis in T2DM rats, whereas meanwhile the levels of NLRP3, active caspase-1, NF-κB, and interleukin-1β were elevated. All these abnormal alterations could be largely reversed after treatment of short hairpin RNA (shRNA) targeting P2Y12. Our results indicate that the silence of P2Y12 by shRNA may effectively correct the anomalous activity of celiac SND and improve the dysfunctional hepatic glucokinase by counteracting hepatocyte inflammation and likely pyroptosis due to activated NLRP3 inflammasome and caspase-1 signaling, thereby attenuating hyperglycemia in T2DM rats. Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Citation

Lin Li, Jingjian Yang, Baoe Liu, Yuting Zou, Minghao Sun, Zijing Li, Runan Yang, Xiumei Xu, Lifang Zou, Guilin Li, Shuangmei Liu, Guodong Li, Shangdong Liang. P2Y12 shRNA normalizes inflammatory dysfunctional hepatic glucokinase activity in type 2 diabetic rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020 Dec;132:110803